Edgewise’s stock surges as heart drug passes early safety test
Edgewise Therapeutics has unveiled early safety data for its rare heart disease drug, with results suggesting it could do away with a black box warning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
